Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions2 holders · as of Mar 31, 2026 | ≥ 659.95% | 151.3K ADS | |
| Adds to | 659.95% |
22.9K ADS (1 ADS = 100 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (22.9K in the company's Sep 3, 2026 report, 19.0K elsewhere); stakes use the report.
Institutional filings for PBMWW (10,000% of the company) are not on file here, so the institutional figure is a floor.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
These groups come from separate filings that can overlap, so they add to 659.95%; nothing is left for Other.
Institutions13F, as of Mar 31, 2026
2 holders · 151.3K shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Parallel Advisors, LLC | 151.3K | 659.56% | Jun 3, 2026 | |
| Stonehage Fleming Financial Services Holdings Ltd | 89 | 0.39% | May 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Psyence Labs Ltd. | 30.05% | 13D | Jun 3, 2026 ↗ | |
| Psyence Group Inc. | 14.99% | 13D | Mar 25, 2025 ↗ | |
| White Lion Capital, LLC | 8.93% | 13G | Dec 13, 2024 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.